Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Provided By GlobeNewswire
Last update: Oct 14, 2025
- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile
94.83
-0.02 (-0.02%)
Find more stocks in the Stock Screener
MRUS Latest News and Analysis
